• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma.

作者信息

Sekiguchi Yasunobu, Tsutsumi Hiroki, Gomyo Ayumi, Kudo Masahisa, Iizaki Yoshie, Maseki Nobuo, Kawamura Machiko, Kobayashi Kazuhiko, Nishimura Yu, Kanda Hiroaki, Nitta Hideaki, Noguchi Masaaki, Kobayashi Hirofumi

机构信息

Department of Hematology, Saitama Cancer Center, Saitama, Japan.

Department of Clinical Laboratory Medicine, Saitama Cancer Center, Saitama, Japan.

出版信息

J Clin Exp Hematop. 2023;63(4):262-265. doi: 10.3960/jslrt.23043.

DOI:10.3960/jslrt.23043
PMID:38148017
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10861370/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/438c/10861370/aa3125eb6b45/jslrt-63-262-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/438c/10861370/aa3125eb6b45/jslrt-63-262-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/438c/10861370/aa3125eb6b45/jslrt-63-262-g001.jpg

相似文献

1
Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma.在≥80岁的弥漫性大B细胞淋巴瘤患者中，使用R-mini-CHP联合泊洛妥珠单抗（pola-R-mini-CHP）作为一线治疗方案。
J Clin Exp Hematop. 2023;63(4):262-265. doi: 10.3960/jslrt.23043.
2
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study.泊洛妥珠单抗联合利妥昔单抗、环磷酰胺、多柔比星和泼尼松用于初治弥漫性大B细胞淋巴瘤的疗效与安全性：一项真实世界、多中心、回顾性队列研究
Hematol Oncol. 2025 Jan;43(1):e70017. doi: 10.1002/hon.70017.
3
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.泊洛妥珠单抗联合化疗治疗未经治疗的弥漫性大 B 细胞淋巴瘤
N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14.
4
Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany.在德国未经治疗的弥漫性大 B 细胞淋巴瘤中，与化疗免疫疗法联合使用泊洛妥珠单抗结合物（pola-R-CHP）的成本效益。
Br J Haematol. 2023 Aug;202(4):771-775. doi: 10.1111/bjh.18869. Epub 2023 May 15.
5
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.波洛沙姆单抗维地滨联合化疗免疫治疗未经治疗的弥漫性大 B 细胞淋巴瘤的成本效益分析。
Blood. 2022 Dec 22;140(25):2697-2708. doi: 10.1182/blood.2022016624.
6
Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model.对于先前未经治疗的弥漫性大B细胞淋巴瘤，使用泊洛妥珠单抗维达替尼-利妥昔单抗-环磷酰胺、多柔比星和泼尼松（pola-R-CHP）进行一线治疗在中国是否具有成本效益？一项使用马尔可夫模型的成本效益分析。
BMJ Open. 2025 Jan 20;15(1):e086251. doi: 10.1136/bmjopen-2024-086251.
7
US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.泊洛妥珠单抗维布妥昔单抗用于既往未治疗的弥漫性大B细胞淋巴瘤的美国成本效益分析。
J Med Econ. 2023 Jan-Dec;26(1):1134-1144. doi: 10.1080/13696998.2023.2254640.
8
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.泊洛妥珠单抗联合免疫化疗治疗未经治疗的弥漫性大 B 细胞淋巴瘤患者的开放性、非随机、1b-2 期研究。
Lancet Oncol. 2019 Jul;20(7):998-1010. doi: 10.1016/S1470-2045(19)30091-9. Epub 2019 May 14.
9
FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas.美国食品药品监督管理局批准摘要：泊洛妥珠单抗维达汀用于某些大B细胞淋巴瘤的一线治疗
Clin Cancer Res. 2024 Dec 16;30(24):5521-5526. doi: 10.1158/1078-0432.CCR-24-1729.
10
Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan.泊洛妥珠单抗维泊妥珠单抗联合利妥昔单抗、环磷酰胺、阿霉素和泼尼松龙治疗日本初治弥漫性大B细胞淋巴瘤的成本效益
J Med Econ. 2023 Jan-Dec;26(1):1122-1133. doi: 10.1080/13696998.2023.2254162.

引用本文的文献

1
Successful treatment with Pola-R-mini-CHP for elderly relapsed and refractory mantle cell lymphoma.采用Pola-R-mini-CHP方案成功治疗老年复发难治性套细胞淋巴瘤。
Ann Hematol. 2024 Dec;103(12):5981-5983. doi: 10.1007/s00277-024-06024-z. Epub 2024 Sep 30.

本文引用的文献

1
How I treat diffuse large B-cell lymphoma.我如何治疗弥漫性大 B 细胞淋巴瘤。
ESMO Open. 2023 Feb;8(1):100750. doi: 10.1016/j.esmoop.2022.100750. Epub 2023 Jan 10.
2
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.Polatuzumab vedotin 治疗未经治疗的弥漫性大 B 细胞淋巴瘤：来自 3 期 POLARIX 试验的亚洲亚组人群分析。
Blood. 2023 Apr 20;141(16):1971-1981. doi: 10.1182/blood.2022017734.
3
An evaluation based on relative treatment intensity in older patients treated with reduced-dose R-THP-COP therapy for diffuse large B-cell lymphoma: A multicenter retrospective cohort study.
基于低剂量R-THP-COP方案治疗弥漫性大B细胞淋巴瘤老年患者的相对治疗强度的评估：一项多中心回顾性队列研究
J Geriatr Oncol. 2023 Jan;14(1):101396. doi: 10.1016/j.jgo.2022.10.011. Epub 2022 Nov 1.
4
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.泊洛妥珠单抗联合化疗治疗未经治疗的弥漫性大 B 细胞淋巴瘤
N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14.
5
CD5+ diffuse large B-cell lymphoma: a narrative review.CD5阳性弥漫性大B细胞淋巴瘤：一篇叙述性综述
Leuk Lymphoma. 2021 Dec;62(13):3078-3086. doi: 10.1080/10428194.2021.1953010. Epub 2021 Jul 21.
6
Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review.R-CHOP 剂量强度对弥漫性大 B 细胞淋巴瘤生存结局的影响：一项系统评价。
Blood Adv. 2021 May 11;5(9):2426-2437. doi: 10.1182/bloodadvances.2021004665.
7
Diffuse large B-cell lymphoma in very elderly patients: Towards best tailored treatment - A systematic review.高龄弥漫性大 B 细胞淋巴瘤患者的最佳治疗选择：系统综述
Crit Rev Oncol Hematol. 2021 Apr;160:103294. doi: 10.1016/j.critrevonc.2021.103294. Epub 2021 Mar 3.
8
Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.皮下注射利妥昔单抗- MiniCHOP 与皮下注射利妥昔单抗- MiniCHOP 联合来那度胺治疗 80 岁及以上弥漫性大 B 细胞淋巴瘤患者的比较。
J Clin Oncol. 2021 Apr 10;39(11):1203-1213. doi: 10.1200/JCO.20.02666. Epub 2021 Jan 14.
9
Clinical characteristics and outcomes among 2347 patients aged ≥85 years with major lymphoma subtypes: a Nordic Lymphoma Group study.85 岁及以上主要淋巴瘤亚型患者 2347 例的临床特征和结局：北欧淋巴瘤组研究。
Br J Haematol. 2021 Feb;192(3):551-559. doi: 10.1111/bjh.17250. Epub 2020 Nov 24.
10
Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma.一项全国性理赔数据库分析：日本弥漫性大 B 细胞淋巴瘤患者的治疗模式、费用和生存情况。
PLoS One. 2020 Aug 18;15(8):e0237509. doi: 10.1371/journal.pone.0237509. eCollection 2020.